EE129 Cost-Effectiveness of Ofatumumab Versus Ocrelizumab in Patients With Active Relapsing Multiple Sclerosis in Portugal
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.381
https://www.valueinhealthjournal.com/article/S1098-3015(22)02585-2/fulltext
Section Title :
Section Order :
12186
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02585-2&doi=10.1016/j.jval.2022.09.381